Cardiol Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Cardiol Therapeutics has a total shareholder equity of CA$10.4M and total debt of CA$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CA$17.5M and CA$7.1M respectively.
Key information
0%
Debt to equity ratio
CA$0
Debt
| Interest coverage ratio | n/a |
| Cash | CA$15.89m |
| Equity | CA$10.43m |
| Total liabilities | CA$7.09m |
| Total assets | CA$17.52m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: CT9's short term assets (CA$17.3M) exceed its short term liabilities (CA$7.0M).
Long Term Liabilities: CT9's short term assets (CA$17.3M) exceed its long term liabilities (CA$134.2K).
Debt to Equity History and Analysis
Debt Level: CT9 is debt free.
Reducing Debt: CT9 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CT9 has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: CT9 is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.